Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Swapnil Malekar - Piper Sandler Sam Slutsky - LifeSci Capital Emily Bodnar - H.C. Wainwright Alex Thompson - Stifel Jeff Jones - Oppenheimer Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40928 Ventyx Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2996852 (St ...

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Yasmeen Rahimi - Piper Sandler Michael Yee - Jefferies Josh Schimmer - Evercore ISI Tiago Fauth - Credit Suisse Sam Slutsky - LifeSci Capital Jeff Jones - Oppenheimer Operator Thank you for standing by and welcome to the Venty ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40928 Ventyx Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2996852 (State o ...

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Marty Auster – Chief Financial Officer Raju Mohan – Founder and Chief Executive Officer Bill Sandborn – President and Chief Medical Officers Conference Call Participants Yasmeen Rahimi – Piper Sandler Josh Schimmer – Evercore ISI Michael Yee – Jefferies Tiago Fauth – Credit Suisse Sam Slutsky – LifeSci Capital Jeff Jones – Oppenheimer Operator Good day, and thank you for standing by. Welcome ...

Financial Performance - The company reported net losses of $22.7 million for Q1 2022, compared to $37.6 million for Q1 2021, with an accumulated deficit of $140.5 million as of March 31, 2022[103]. - The net loss for Q1 2022 was $22.7 million, compared to a net loss of $37.6 million in Q1 2021, reflecting an improvement of $14.9 million[122]. - The company has incurred significant operating losses and expects these to continue as it advances its clinical trials and research activities[104]. - The company has not generated any revenue since its inception and does not expect to do so until successful completion of clinical development and regulatory approval of its product candidates[113]. - The company has not generated any revenue to date and does not expect to until regulatory approval of its product candidates[133]. Research and Development - Research and development expenses totaled $17.4 million for Q1 2022, a decrease from $24.6 million in Q1 2021, with significant costs attributed to VTX958, VTX002, and VTX2735[115]. - Research and development expenses decreased from $24.6 million in Q1 2021 to $17.4 million in Q1 2022, a reduction of $7.2 million[122][123]. - The total cost of asset acquisitions for Oppilan and Zomagen was $14.0 million and $7.8 million, respectively, with excess costs of $12.8 million and $8.9 million expensed as in-process research and development[112]. - The company is currently conducting a Phase 2 trial of VTX002 for moderate-to-severe ulcerative colitis, with enrollment impacted by the conflict in Ukraine[107]. - The company plans to initiate Phase 2 trials for VTX958 in the second half of 2022 for indications including psoriasis and Crohn's disease[101]. Cash Flow and Financing - Cash, cash equivalents, and marketable securities totaled $273.1 million as of March 31, 2022[131]. - Net cash used in operating activities was $12.7 million in Q1 2022, compared to $3.0 million in Q1 2021[142][143]. - Net cash used in investing activities was $16.5 million in Q1 2022, primarily due to the purchase of investments in marketable securities[144]. - Net cash provided by financing activities was $0.1 million for the three months ended March 31, 2022, compared to $56.9 million for the same period in 2021, primarily due to proceeds from the issuance of Series A Preferred Stock[145]. - The company has funded operations through $164.2 million in convertible preferred stock and $158.8 million from its IPO[131]. - The company expects that its current cash resources will fund operations into the first half of 2024[135]. Operating Expenses - General and administrative expenses are expected to increase as the company expands operations and complies with public company requirements[119]. - General and administrative expenses increased significantly from $0.7 million in Q1 2021 to $5.3 million in Q1 2022, an increase of $4.6 million[125]. - The company anticipates significant increases in expenses related to ongoing development activities and commercialization efforts[133][134]. Company Classification and Reporting - The company remains an "emerging growth company" until annual gross revenue reaches $1.07 billion or more, or until the end of 2026[149]. - The company is classified as a "smaller reporting company" as the market value of its stock held by non-affiliates is less than $700 million as of June 30, 2021, and annual revenue was below $100 million for the fiscal year ended December 31, 2021[150]. - The company has elected to take advantage of reduced reporting requirements under the JOBS Act, which may affect the comparability of its financial statements[148]. - The company may continue to rely on exemptions from certain disclosure requirements as a smaller reporting company[150]. - As a smaller reporting company, the company is not required to provide quantitative and qualitative disclosures about market risk[152]. Accounting Policies - There have been no material changes to critical accounting policies and estimates from those described in the previous Annual Report[147]. - Recent accounting pronouncements that may impact financial positions or cash flows are disclosed in Note 2 of the condensed consolidated financial statements[151].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40928 Ventyx Biosciences, Inc. | (Exact Name of Registrant as Specified in its Charter) | | | --- | --- | | Delaware | 83-2996852 | | ...

CORPORATE PRESENTATION FIRST QUARTER 2022 Forward Looking Statements Ventyx cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on Ventyx's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: management's belief that three of Ventyx's product candidates are potentially best-in-class; the anticipated timing of commencement, enr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: | | Trading | | | --- | --- | --- | | Title of each class | Symbol(s) | Name of each exchange on which registered | | Common St ...